Bon Secours Cancer Institute at St. Francis ( Site 0048), Midlothian
Virginia Oncology Associates (VOA) ( Site 8008), Norfolk
Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8005), Roanoke

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06966700

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Mary Washington Hospital ( Site 0129), Fredericksburg
Hematology Oncology Associates of Fredericksburg ( Site 9550), Fredericksburg
Bon Secours Memorial Regional Medical Center-Oncology Research Department ( Site 0020), Midlothian
и уште 2

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06393374

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Virginia Oncology Associates (VOA) ( Site 8002), Norfolk

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06841354

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Virginia Cancer Specialists, Fairfax

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 21.9.2026 · NCT05983432

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

University of Virginia, Charlottesville
Inova Fairfax Hospital, Fairfax
Bon Secours Cancer Institute at St. Francis, Midlothian
и уште 1

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT05633654

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

VCU Massey Comprehensive Cancer Center, Richmond

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT03606967

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

NEXT Virginia, Fairfax

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 28.8.2026 · NCT07029399

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Research Site, Fairfax

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 19.8.2026 · NCT07115043

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Normunity Investigational Site, Fairfax

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 18.8.2026 · NCT07182149

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Bon Secours St. Francis Medical Center, Midlothian
Local Institution - 0301, Roanoke
Shenandoah Oncology, P.C., Winchester

Се регрутираФаза 2/3

Возраст 18 и постари · Сите полови · Ажурирано 10.8.2026 · NCT06926868

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

Clinical Trial Site, Fairfax

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 6.8.2026 · NCT07749586

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

USOR Virginia Cancer Specialists, Fairfax
USOR Virginia Oncology Associates, Norfolk

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 4.8.2026 · NCT05579366

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

NEXT Virginia, Fairfax

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 22.7.2026 · NCT05208762

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

University of Virginia Comprehensive Cancer Center, Charlottesville

Се регрутираФаза 2

Возраст 18 и постари · Жени · Ажурирано 21.7.2026 · NCT04348747

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

NEXT Oncology Virginia, Fairfax

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 29.6.2026 · NCT05377996

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Virginia Cancer Specialists - Fairfax /ID# 232592, Fairfax

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 23.6.2026 · NCT05005403

A Study of LY4175408 in Participants With Advanced Cancer

NEXT Virginia, Fairfax

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 23.6.2026 · NCT07046923

Study of XB010 in Subjects With Solid Tumors

Inova Schar Cancer, Fairfax
NEXT Virginia, Fairfax

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 22.6.2026 · NCT06545331

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

NEXT Texas LLC - Virginia, Fairfax

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 18.6.2026 · NCT07503808

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Virginia Oncology Associates, Norfolk

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 30.1.2026 · NCT06926920

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Dren Investigational Site, Fairfax

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 7.1.2026 · NCT06999187

A Study of NX-1607 in Adults With Advanced Malignancies

University of Virginia, Charlottesville

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 9.9.2025 · NCT05107674

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

Next Oncology, Virginia Cancer Specialists, Fairfax

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 26.1.2024 · NCT05746897

Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.